Buy DMBMPP Cas 1391499-52-7

Buy DMBMPP Cas 1391499-52-7

DMBMPP, also known as juncosamine or as 2-(2,5-dimethoxy-4-bromobenzyl)-6-(2-methoxyphenyl)piperidine, is a highly selective serotonin 5-HT_2A receptor agonist and 2-benzylpiperidine analogue of the serotonergic psychedelic 25B-NBOMe which is used in scientific research.^[1][2][3][4]

The (S,S)-isomer ((2S,6S)-DMBMPP) is the most selective agonist for the human serotonin 5-HT_2A receptor yet discovered, with a affinity (K_i) of 2.5 nM at the human serotonin 5-HT_2A receptor and with 124-fold selectivity for the serotonin 5-HT_2A receptor over the structurally similar serotonin 5-HT_2C receptor.^[4][5] Together with 25CN-NBOH,^[6] (2S,6S)-DMBMPP is the only known 5-HT_2A agonist to exhibit this level of selectivity.^[7] In contrast to the case of the serotonin 5-HT_2A receptor, no functional data has been reported for DMBMPP at the serotonin 5-HT_2C receptor as of 2023.^[8][7]

Ligand	Ki ± SEM (nM)	Ki ± SEM (nM)	Ki ± SEM (nM)
	[3H] ketanserin	[3H] mesulergine	fold selectivity
	h5-HT2A	h5-HT2C	h5-HT2C/h5-HT2A
2C-B	6.0 ± 0.3	23.8 ± 2.6	9.5
25B-NBOMe	0.19 ± 0.01	4.0 ± 0.4	21
(±)-DMBMPP	5.3 ± 0.3	520 ± 22	98
(S,S)-(−)-DMBMPP	2.5 ± 0.1	310 ± 42	124
(R,R)-(+)-DMBMPP	2,100 ± 171	28,600 ± 4700	27

(S,S)-DMBMPP was assessed and found to fully substitute for the psychedelic drug LSD in rodent drug discrimination tests.^[9][10][4] As such, DMBMPP may be expected to have hallucinogenic effects in humans.^[9][10][4]

Despite its uniquely high selectivity for the serotonin 5-HT_2A receptor, it has been said that DMBMPP is not widely used as a pharmacological tool in scientific research, presumably due to its chemical synthesis being relatively inaccessible.^[7] Consequently, 25CN-NBOH, another highly selective serotonin 5-HT_2A receptor agonist, has been proposed as an alternative to DMBMPP for use in scientific research.^[7] DMBMPP and 25CN-NBOH are the two most selective serotonin 5-HT_2A receptor agonists known as of 2020.^[11]

DMBMPP, also known as 2-(2,5-dimethoxy-4-bromobenzyl)-6-(2-methoxyphenyl)piperidine, is a cyclized phenethylamine, 2C, and NBOMe derivative of 2C-B and 25B-NBOMe.^[2] It differs from 25B-NBOMe by incorporating the amine within a piperidine ring, making for a more conformationally restrained, rigid molecular structure than that of the open-chain 25B-NBOMe.^[2] The presence of the piperidine ring introduces two stereocenters, thus, four stereoisomers of this compound can be made.^[2]

DMBMPP was first described in the scientific literature by Jose Juncosa of the lab of David E. Nichols at Purdue University in 2011.^[3][4]

DMBMPP is not an explicitly controlled substance in Canada as of 2025.^[12] However, it might be covered under phenethylamine and amphetamine blanket-ban language, although this is unclear due to its nature as a cyclized phenethylamine.^[12]

DMBMPP is not an explicitly controlled substance in the United States.^[13] However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.